{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:04:06Z","timestamp":1780574646550,"version":"3.54.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Oncology"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/s1470-2045(09)70025-7","type":"journal-article","created":{"date-parts":[[2009,3,10]],"date-time":"2009-03-10T05:46:10Z","timestamp":1236663970000},"page":"459-466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6527,"title":["Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial"],"prefix":"10.1016","volume":"10","author":[{"given":"Roger","family":"Stupp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika E","family":"Hegi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren P","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J","family":"van den Bent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin JB","family":"Taphoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C","family":"Janzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel K","family":"Ludwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk","family":"Allgeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Belanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba A","family":"Brandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Gijtenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Marosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J","family":"Vecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Mokhtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Wesseling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Eisenhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Gorlia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Gregory","family":"Cairncross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9-Olivier","family":"Mirimanoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S1470-2045(09)70025-7_bib1","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJM198012043032303","article-title":"Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery","volume":"303","author":"Walker","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(09)70025-7_bib2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0167-8140(02)00078-6","article-title":"Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review","volume":"64","author":"Laperriere","year":"2002","journal-title":"Radiother Oncol"},{"key":"10.1016\/S1470-2045(09)70025-7_bib3","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(02)08091-1","article-title":"Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials","volume":"359","author":"Stewart","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/S1470-2045(09)70025-7_bib4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(09)70025-7_bib5","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(09)70025-7_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2307\/2529712","article-title":"Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial","volume":"31","author":"Pocock","year":"1975","journal-title":"Biometrics"},{"key":"10.1016\/S1470-2045(09)70025-7_bib7","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2307\/2529759","article-title":"On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial","volume":"32","author":"Freedman","year":"1976","journal-title":"Biometrics"},{"key":"10.1016\/S1470-2045(09)70025-7_bib8","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.ejca.2004.03.026","article-title":"Quality assurance of the EORTC 26981\/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review","volume":"40","author":"Ataman","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/S1470-2045(09)70025-7_bib9","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S1470-2045(05)70432-0","article-title":"Health-related quality of life in patients with glioblastoma: a randomised controlled trial","volume":"6","author":"Taphoorn","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1470-2045(09)70025-7_bib10","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2005.04.5963","article-title":"Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981\/22981-NCIC CE3 phase III randomized trial","volume":"24","author":"Mirimanoff","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70025-7_bib11","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/cncr.23297","article-title":"Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981\/22981 NCI-C CE3 Intergroup Study","volume":"112","author":"Lamers","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(09)70025-7_bib12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/0167-8140(94)90095-7","article-title":"Accelerated radiotherapy in glioblastoma multiforme: a dose searching prospective study","volume":"32","author":"Gonzalez","year":"1994","journal-title":"Radiother Oncol"},{"key":"10.1016\/S1470-2045(09)70025-7_bib13","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1200\/JCO.1999.17.10.3143","article-title":"Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933","volume":"17","author":"Miralbell","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70025-7_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0305-7372(97)90019-0","article-title":"Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials","volume":"23","author":"Newlands","year":"1997","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/S1470-2045(09)70025-7_bib15","first-page":"4363","article-title":"Phase I trial of temozolomide using an extended continuous oral schedule","volume":"58","author":"Brock","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/S1470-2045(09)70025-7_bib16","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1054\/bjoc.2000.1316","article-title":"A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse","volume":"83","author":"Yung","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/S1470-2045(09)70025-7_bib17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1008382516636","article-title":"Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse","volume":"12","author":"Brada","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(09)70025-7_bib18","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1200\/JCO.2002.20.5.1375","article-title":"Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide","volume":"20","author":"Stupp","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70025-7_bib19","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1215\/15228517-2008-058","article-title":"A novel tool to analyse MRI recurrence patterns in glioblastoma","volume":"10","author":"Wick","year":"2008","journal-title":"Neuro Oncol"},{"key":"10.1016\/S1470-2045(09)70025-7_bib20","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2007.14.8163","article-title":"MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients","volume":"26","author":"Brandes","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70025-7_bib21","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.2001.19.2.509","article-title":"Randomized trial of procarbazine, lomustine and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial","volume":"19","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70025-7_bib23","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/00001813-199701000-00013","article-title":"In vitro evaluation of temozolomide combined with X-irradiation","volume":"8","author":"Wedge","year":"1997","journal-title":"Anticancer Drugs"},{"key":"10.1016\/S1470-2045(09)70025-7_bib24","first-page":"1957","article-title":"p53 effects both the duration of G2\/M arrest and the fate of temozolomide-treated human glioblastoma cells","volume":"61","author":"Hirose","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/S1470-2045(09)70025-7_bib25","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0360-3016(99)00539-8","article-title":"Survival of human glioma cells treated with various combination of temozolomide and X-rays","volume":"47","author":"van Rijn","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/S1470-2045(09)70025-7_bib26","first-page":"1915","article-title":"Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase","volume":"62","author":"Wick","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/S1470-2045(09)70025-7_bib27","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1158\/1078-0432.CCR-06-0596","article-title":"Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms","volume":"12","author":"Chakravarti","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S1470-2045(09)70025-7_bib28","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/85.9.704","article-title":"Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials","volume":"85","author":"Curran","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S1470-2045(09)70025-7_bib29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0140-6736(03)12328-8","article-title":"Primary brain tumours in adults","volume":"361","author":"Behin","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/S1470-2045(09)70025-7_bib30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(07)70384-4","article-title":"Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981\/CE.3","volume":"9","author":"Gorlia","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1470-2045(09)70025-7_bib31","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1470-2045(06)70665-9","article-title":"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial","volume":"7","author":"Stummer","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1470-2045(09)70025-7_bib32","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S1470-2045(08)70134-7","article-title":"How not to treat cancer","volume":"9","author":"Schilsky","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1470-2045(09)70025-7_bib33","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1200\/JCO.2002.06.110","article-title":"Clinical relevance of MGMT in the treatment of cancer","volume":"20","author":"Gerson","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70025-7_bib34","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nrc1319","article-title":"MGMT: its role in cancer aetiology and cancer therapeutics","volume":"4","author":"Gerson","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/S1470-2045(09)70025-7_bib35","first-page":"5815","article-title":"Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9\/3 regulated and Fas\/caspase-8 independent","volume":"60","author":"Ochs","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/S1470-2045(09)70025-7_bib36","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM200011093431901","article-title":"Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents","volume":"343","author":"Esteller","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(09)70025-7_bib37","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1158\/1078-0432.CCR-03-0384","article-title":"Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide","volume":"10","author":"Hegi","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S1470-2045(09)70025-7_bib38","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1200\/JCO.1998.16.10.3310","article-title":"Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study","volume":"16","author":"Jaeckle","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70025-7_bib39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11060-006-9320-0","article-title":"MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities","volume":"83","author":"Criniere","year":"2007","journal-title":"J Neurooncol"},{"key":"10.1016\/S1470-2045(09)70025-7_bib40","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2007.11.5964","article-title":"Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity","volume":"26","author":"Hegi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70025-7_bib41","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2007.15.7164","article-title":"Stem cell-related \u00abself-renewal\u00bb signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma","volume":"26","author":"Murat","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70025-7_bib42","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-06-2309","article-title":"Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma","volume":"13","author":"Vredenburgh","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S1470-2045(09)70025-7_bib43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","article-title":"AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients","volume":"11","author":"Batchelor","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/S1470-2045(09)70025-7_bib44","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70025-7_bib45","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1200\/JCO.2007.11.8554","article-title":"Chemoradiotherapy in malignant glioma: standard of care and future directions","volume":"25","author":"Stupp","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70025-7_bib46","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1200\/JCO.2008.16.7510","article-title":"Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme","volume":"26","author":"Reardon","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70025-7_bib47","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1517\/13543784.17.8.1225","article-title":"Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme","volume":"17","author":"Reardon","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/S1470-2045(09)70025-7_bib48","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1158\/1535-7163.MCT-07-0047","article-title":"Lessons learned in the development of targeted therapy for malignant gliomas","volume":"6","author":"Omuro","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"suppl","key":"10.1016\/S1470-2045(09)70025-7_bib49","first-page":"75s","article-title":"Phase I\/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients with newly diagnosed glioblastoma","volume":"25","author":"Stupp","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70025-7_bib50","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMra0708126","article-title":"Malignant gliomas in adults","volume":"359","author":"Wen","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(09)70025-7_bib51","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2008.17.5984","article-title":"Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma","author":"van den Bent","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["The Lancet Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204509700257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204509700257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:00:10Z","timestamp":1761458410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204509700257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S1470204509700257"],"URL":"https:\/\/doi.org\/10.1016\/s1470-2045(09)70025-7","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1162488.624014","asserted-by":"object"}]},"ISSN":["1470-2045"],"issn-type":[{"value":"1470-2045","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(09)70025-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(09)70124-X","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}